top of page
DELIVERING VALUE FOR PATIENTS AND INVESTORS
Harnessing our unique investment approach focused on the translational stage of drug development, combined with our agile operating model for company formation and trial execution, Aditum Bio has launched seven companies to date.
FUND I SNAPSHOT
Launched in 2019, Fund 1 is fully invested in the formation of six portfolio companies.
FUND II SNAPSHOT
Launched in 2021, Fund II is currently deploying capital to form new, innovative companies to meet the needs of patients
bottom of page